BMS' big merger bet is still on with latest CAR-T filing

Bristol-Myers Squibb and development partner bluebird bio have filed their multiple myeloma CAR-T with the FDA, the final part of a three-drug “bet” that was a sweetener following its $74 b

Takeda's Ninlaro falls short in first line multiple myeloma

Takeda’s Ninlaro (ixazomib) has fallen short in a late-stage study testing it in combination with Bristol-Myers Squibb/Celgene’s Revlimid and chemo in newly diagnosed multiple myeloma.

BMS/AbbVie's combo falls short in untreated multiple myeloma...

Adding Bristol-Myers Squibb/AbbVie's Empliciti to Revlimid, developed by BMS' recently acquired Celgene unit, does not improve survival in untreated multiple myeloma, a study has shown.

Sanofi gets first OK for isatuximab for myeloma, challenging...

Janssen's Darzalex approved in EU for newly-diagnosed multip...

Janssen’s Darzalex (daratumumab) has been approved in Europe as a combination therapy in newly-diagnosed patients with multiple myeloma.

Life with multiple myeloma

Multiple myeloma patient Bob Munro (pictured below) explains what it's like to live with the rare blood cancer and how his diagnosis led him on the journey of a lifetime – cycling from